Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529113 · ClinicalTrials.gov registry record · Phase 1
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
A Phase 1 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00529113 is a Phase 1 study that was terminated before completion, run by Biogen. The registered enrollment target is 33 participants.
The verdict
NCT00529113, a Phase 1 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.
Interventions
- DRUG Bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-09-30 |
| Est. Completion | 2009-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529113
The ClinicalTrials.gov registry entry for NCT00529113 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bardoxolone methyl is the first listed.
NCT00529113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529113 about?
NCT00529113 is a clinical study titled "Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer". This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.
What is the current status of trial NCT00529113?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2007-09-30. Estimated completion is 2009-11-01.
What interventions are being tested in trial NCT00529113?
The interventions under investigation include: Bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT00529113?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.